Edity Therapeutics

About

Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health.

The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function. Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.

Funding history · 3 rounds · $13.6M total

2023-12

Series A $11.1M

2023-10

Equity crowdfunding $252K

2021-09

Seed $2.3M

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

BiologicalsGenes

Target customers

Healthcare & Life SciencesLife SciencesBiotechnology

Business model

B2B

Edity Therapeutics — Full Company Profile (machine-readable)

Using Human Immune Cells to Deliver Therapeutic Proteins

About

Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health. The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function. Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.

Facts

Name	Edity Therapeutics
Slug	edity-therapeutics
Type	Israeli Startup
Founded	2019
HQ city	Rehovot
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Target customers	[object Object], [object Object], [object Object]
Status	active
Current stage	Series A
Public stage	A
Total raised (USD)	13,632,300
Last round	Series A (2023-12)
Website	https://edity-tx.com
Crunchbase ID	edity-therapeutics
Israeli Companies Registrar	516095270

Funding rounds (3)

Date	Round	Amount	All investors
2021-09	Seed	$2,280,000	NFX Capital, Tal Ventures
2023-10	Equity crowdfunding	$252,300	OurCrowd, Loop Ventures, Reinforced Ventures, Gaingels
2023-12	Series A	$11,100,000	Dr. Reddy's Laboratories

Team (4)

Name	Role	LinkedIn
Eyal Kolka
Michal Golan Mashiach
Yoav Manaster
Nurit Naor

News mentions (1)

Jan 16, 2024 — www.webwire.com: Article

About

Funding history · 3 rounds · $13.6M total

Sectors & technology

Highlights

Tags